LCN2 and breast cancer: In supportive of our hypothesis, higher LCN2 expression was associated with worse DSS (HR 1.36, 95% CI 1.09–1.57, p = 0.003), PFI (HR = 1.31, (95% CI = 1.134–1.65, p = 0.001), but not for OS (p = 0.43) among breast cancer patients of the METABRIC cohort (Figure 4D).